In a study by Russell et al. (19), low-stage NB was unlikely to have metastatic disease in the BM, and therefore they recommended further investigation of the genetic factors such as MYCN amplification and chromosome 1p deletion in order to better predict which tumors are at risk of metastatic spread. The gene discussed is MYCN; the disease is neuroblastoma.